CML is characterised by a reciprocal translocation t(9;22) resulting in the Philadelphia chromosome.4 This hallmark genetic alteration in CML is essential for diagnosis of this chronic myeloproliferative neoplasm.5 This t(9;22) resulting in BCR-ABL fusion gene is detected by RT-PCR or fluorescent in situ hybridisation on molecular analysis while the resulting Ph Chromosome can be detected on conventional cytogenetics.6 Thus, these not only are necessary for establishing diagnosis but also have a pivotal role in disease monitoring, thus allowing clinicians to make treatment decisions7. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.